Billhofer v. Flamel Technologies, S.A.

281 F.R.D. 150, 2012 WL 928147, 2012 U.S. Dist. LEXIS 36996
CourtDistrict Court, S.D. New York
DecidedMarch 15, 2012
DocketNo. 07 Civ. 9920
StatusPublished
Cited by12 cases

This text of 281 F.R.D. 150 (Billhofer v. Flamel Technologies, S.A.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Billhofer v. Flamel Technologies, S.A., 281 F.R.D. 150, 2012 WL 928147, 2012 U.S. Dist. LEXIS 36996 (S.D.N.Y. 2012).

Opinion

OPINION

SWEET, District Judge.

Lead Plaintiff George Jenkins (“Plaintiff’ or “Proposed Class Representative”) has moved pursuant to Rules 23(a) and 23(b)(3) of the Federal Rules of Civil Procedure for class certification, certification of class representative, and appointment of class counsel.

Based on the facts and conclusions set forth below, Plaintiffs motion is granted, the class and class representatives are certified and co-class counsel are appointed.

[153]*153 I. Prior Proceedings

The complaint in this putative class action, alleging securities fraud against Flamel Technologies S.A. (“Flamel”) and four of its principals (collectively “Defendants”), was filed on November 9, 2007. This action arose out of the March 2007 commercial launch of COREG CR, a drug developed by GlaxoSmithKline (“GSK”), which employed Flamel’s “micropump” for drug delivery. COREG CR was intended to supplant COREG IR, another drug GSK had developed but whose patent exclusivity was expiring in September 2007, exposing it to generic competition. The primary advantage of COREG CR over COREG IR was that CR (for “controlled release”) allowed for once daily dosages compared with IR (for “immediate release”) which required twice daily dosages.

Both before and during the proposed class period, from March 23, 2007 to August 22, 2007 (the “Class Period”), a number of clinical studies relating to COREG CR were conducted. One of those studies, known as the “CASPER” trial, compared patients’ compliance with their doctors’ prescriptions using COREG IR versus COREG CR. The CAS-PER trial found no statistically significant difference in patients’ compliance rates. Plaintiff identifies certain positive statements regarding COREG CR made during the Class Period and alleges that Defendants knew or recklessly disregarded the CASPER trial results. Plaintiff alleges that the abstract of the CASPER trial was published in the Journal of Cardiac Failure on or about August 23, 2007. According to the Amended Complaint, Flamel’s ADR price dropped from $12.68 to $9.56 per share on August 23, 2007 in response to this news.

On February 11, 2008, the Honorable Charles S. Haight appointed plaintiff Christel Billhofer (“Billhofer”) as Lead Plaintiff in this action and appointed the law firm of Coughlin Stoia Geller Rudman Robbins LLP1 (“Coughlin Stoia”) as Lead Counsel. On March 27, 2008, Plaintiff filed a First Amended Complaint. On October 5, 2009, Judge Haight denied Defendants’ motion to dismiss. See Billhofer v. Flamel Techs., SA, 663 F.Supp.2d 288 (S.D.N.Y.2009). The action was subsequently reassigned.

On January 22, 2010, Billhofer filed a motion for class certification, her certification as class representative, and appointment of Coughlin Stoia as class counsel. After filing the motion, Billhofer advised that she would no longer be able to serve in a representative capacity on behalf of the proposed class and thus Defendants did not file opposing briefs, nor did the Court rule, on Billhofer’s certification motion.

On April 29, 2010, Billhofer moved, inter alia, to withdraw as Lead Plaintiff, substitute Jenkins in her stead, and approve Jenkins’ selection of the law firm of Barroway Topaz as co-lead counsel. On June 23, 2010, the claims against individual defendant Rafael Jorda were voluntarily dismissed. On September 21, 2010, the Court granted Billhofer’s motion for substitution and on October 1, 2010, appointed Barroway Topaz as co-lead counsel.

The instant motion was heard on September 21, 2011.

II. The Facts

The following facts are drawn from affidavits submitted and are not in dispute except as noted below.

During the Class Period, Flamel had at least 23 million American Depository Receipts (“ADRs”) outstanding, owned by hundreds if not thousands of persons, with such ADRs actively trading on the NASDAQ Stock Market (“NASDAQ”). There were between 71 and 82 institutional investors who are members of the putative Class. During the Class Period, Flamel had an average weekly trading volume of at least 9.2% of outstanding shares.

During the Class Period, Flamel was followed by numerous securities analysts employed by major brokerage firms. Eight separate firms issued reports about Flamel and four additional firms (including Merrill [154]*154Lynch) participated in investor conference calls hosted by Flamel and more than two dozen articles and press releases were published about Flamel.

Flamel had at least 41 companies serving as market makers on the NASDAQ for its stock during the Class Period. This number of market makers was almost twice the average number of market makers for all NASDAQ securities during the same time period. From March through August, 2007, the average number of market makers for all NASDAQ securities was 21. This average includes market makers who accounted for less than one percent of a security’s activity. During this same period, 21 market makers each accounted for at least one percent of the NASDAQ activity in Flamel ADRs. Another 20 market makers each accounted for less than one percent of NASDAQ activity in Flamel.

During the Class Period, Flamel met the two market efficiency-related requirements of Form S-3 — at least a 12-month reporting history and a minimum $75 million in public float. During that time, Flamel’s total market capitalization ranged from $288 million to $717 million. The vast majority (ie., more than 99.4%) of Flamel’s ADRs were held by the public, as opposed to by insiders. At its lowest point during the Class Period, Flamel’s public float exceeded $286 million. Flamel was eligible to file, and in 2003 did file, a Form F-3, the foreign entity’s functional equivalent of the Form S-3. See, e.g., In re SCOR Holding (Switzerland) AG Litig., 537 F.Supp.2d 556, 578 n. 35 (S.D.N.Y. 2008) (“as a foreign issuer, the equivalent [of a Form S-3] would have been a Form F-3”); see also Form S-3, 17 C.F.R. § 239.13; Form F-3, 17 C.F.R. § 239.33 (both requiring a twelve-month reporting history and $75 million in market capitalization). During the Class Period, the average bid-ask spread for Flamel was 0.198%.

On August 23, 2007, the day on which an abstract of the CASPER Trial was published, the price of Flamel ADRs fell by 24.6% percent, while the NASDAQ Composite Index and the NASDAQ Biotechnology Index decreased by 0.43 percent and 0.14 percent, respectively.

Ten days earlier, on August 13, 2007, the j CASPER abstract was placed on a subpage of a conference supplement on the website of the Journal of Cardiac Failure. The conference supplement contained the results of over 400 different clinical trials and did not mention Flamel. The CASPER abstract was number 209 of those abstracts. The record does not establish who was responsible for online posting for The Journal of Cardiac Failure in 2007 and the records of Elsevier, Inc., the publisher of the Journal of Cardiac Failure, do not reflect the online posting of the Supplement on August 13, 2007.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Angley v. UTI Worldwide Inc.
311 F. Supp. 3d 1117 (C.D. California, 2018)
Strougo v. Barclays PLC
312 F.R.D. 307 (S.D. New York, 2016)
In re Facebook, Inc.
312 F.R.D. 332 (S.D. New York, 2015)
Carpenters Pension Trust Fund v. Barclays PLC
310 F.R.D. 69 (S.D. New York, 2015)
McIntire v. China MediaExpress Holdings, Inc.
38 F. Supp. 3d 415 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
281 F.R.D. 150, 2012 WL 928147, 2012 U.S. Dist. LEXIS 36996, Counsel Stack Legal Research, https://law.counselstack.com/opinion/billhofer-v-flamel-technologies-sa-nysd-2012.